Premenstrual syndrome: a review of the literature


Cite item

Full Text

Abstract

Premenstrual syndrome is defined as a combination of physical and mental symptoms that have a significant impact on a woman’s quality of life and develop into the second phase of the menstrual cycle. Many patients have not been diagnosed, and therefore pathogenetic treatment is not carried out, although these complaints may disrupt the daily lives of patients and relationships with others. The article presents a review of the literature and studies that assessed the effectiveness of various treatment options (antidepressants, hormone therapy, lifestyle modification and herbal therapy).

About the authors

Elena N Andreeva

Endocrinology Research Centre; A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: endogin@mail.ru
D. Sci. (Med.), Prof. Moscow, Russia

Yulia S Absatarova

Endocrinology Research Centre

Email: korsil2008@yandex.ru
Res. Officer Moscow, Russia

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Arlington VA: 2013. American Psychiatric Publishing.
  2. Hartlage S, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69: 300-5. doi: 10.1001/archgenpsychiatry.2011.1368
  3. Вольфф М. Гинекологическая эндокринология и репродуктивная медицина. Пер. с нем. под общ. ред. Е.Н.Андреевой. М.: МЕДпресс-информ, 2017.
  4. Appleton S.M. Premenstrual Syndrome: Evidence-based Evaluation and Treatment. Clin Obstet Gynecol 2018; 61 (1): 52-61. doi: 10.1097/GRF.0000000000000339
  5. Heinemann L.A, Mihn T.D, Heinemann K et al. Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women Int 2012; 33: 109-24. doi: 10.1080/07399332.2011.610530
  6. Chocano-Bedoya P.O, Manson J.E, Hankinson S.E et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr 2011; 93 (5): 1080-6. doi: 10.3945/ajcn.110.009530
  7. Hashemi S, Ramezani Tehrani F, Mohammadi N et al. Comparison of Metabolic and Hormonal Profiles of Women With and Without Premenstrual Syndrome: A Community Based Cross-Sectional Study. Int J Endocrinol Metab 2016; 14: e28422. doi: 10.5812/ijem.28422
  8. Bertone-Johnson E, Hankinson S, Willett W et al. Adiposity and the development of premenstrual syndrome. J Womens Health (Larchmt) 2010; 19: 1955-62. doi: 10.1089/jwh.2010.2128
  9. Perkonigg A, Yonkers K, Pfister H et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65: 1314-22.
  10. Graze K, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81: 201-5.
  11. Kendler K, Silberg J, Neale M et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992; 22: 85-100.
  12. Schmidt P, Martinez P, Nieman L et al. Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. Am J Psychiatry 2017: appiajp201716101113. doi: 10.1176/appi.ajp.2017.16101113
  13. Bixo M, Ekberg K, Poromaa I.S et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology 2017; 80: 46-55. doi: 10.1016/j.psyneuen.2017.02.031
  14. Gracia C, Freeman E, Sammel M et al. Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol 2009; 29: 403-5. doi: 10.1097/JCP.0b013e3181ad8825
  15. Eriksson E. SSRIs probably counteract premenstrual syndrome by inhibiting the serotonin transporter. J Psychopharmacol 2014; 28: 173-4. doi: 10.1177/0269881113512910
  16. Hiroi R, Mcdevitt R, Neumaier J.F. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 2006; 60: 288-95.
  17. Bertone-Johnson E.R, Whitcomb B.W, Rich-Edwards J.W et al. Premenstrual Syndrome and Subsequent Risk of Hypertension in a Prospective Study. Am J Epidemiol 2015; 182 (12): 1000-9. doi: 10.1093/aje/kwv159
  18. Bertone-Johnson E.R, Houghton S.C, Whitcomb B.W et al. Association of Premenstrual Syndrome with Blood Pressure in Young Adult Women. J Womens Health (Larchmt) 2016; 25 (11): 1122-8.
  19. Liu R, Mi B, Zhao Y et al. Effect of B Vitamins from Diet on Hypertension. Arch Med Res 2017; 48 (2): 187-94. doi: 10.1016/j.arcmed.2017.03.011
  20. Bender A, Hagan K.E, Kingston N. The association of folate and depression: A meta-analysis. J Psychiatr Res 2017; 95: 9-18. doi: 10.1016/j.jpsychires.2017.07.019
  21. Briguglio M, Dell'Osso B, Panzica G et al. Dietary Neurotransmitters: A Narrative Review on Current Knowledge. Nutrients 2018; 10 (5). pii: E591. doi: 10.3390/nu10050591
  22. Isgin-Atici K, Buyuktuncer Z, Akgül S, Kanbur N. Adolescents with premenstrual syndrome: not only what you eat but also how you eat matters! J Pediatr Endocrinol Metab 2018; 31 (11): 1231-9. doi: 10.1515/jpem-2018-0125
  23. Farasati N, Siassi F, Koohdani F et al. Western dietary pattern is related to premenstrual syndrome: a case-control study. Br J Nutr 2015; 114: 2016-21. doi: 10.1017/S0007114515003943
  24. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41-9.
  25. Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt) 2009; 18: 895-9. doi: 10.1089/jwh.2008.1098
  26. Green L, O' Brien P, Panay N, Craig M. Gynaecologists RCOOA. Management of premenstrual symptoms. Br J Obst Gynaecol 2016; 124: e73-e105.
  27. Hunter M, Ussher J, Browne S et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193-9.
  28. Whelan A.M, Jurgens T.M, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: e407-e429.
  29. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322: 134-7.
  30. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment ofpremenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18: 191-5.
  31. Marjoribanks J, Brown J, O’Brien P.M, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013; 6: CD 001396. doi: 10.1002/14651858. CD001396.pub3
  32. Freeman E.W, Rickels K, Yonkers K.A et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98 (pt 1): 737-44.
  33. Nevatte T, O’Brien P.M, Backstrom T et al.; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013; 16: 279-91. doi: 10.1007/s00737-013-0346-y
  34. Hunter M.S, Ussher J.M, Browne S.J et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193-9.
  35. Joffe H, Cohen L.S, Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003; 189: 1523-30.
  36. Pearlstein T.B, Bachmann G.A, Zacur H.A, Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414-21.
  37. Lopez L.M, Kaptein A.A, Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2: CD006586. doi: 10.1002/14651858.CD006586.pub4
  38. Yonkers K.A, Simoni M.K. Premenstrual disorders. Am J Obstet Gynecol 2018; 218 (1): 68-74. doi: 10.1016/j.ajog.2017.05.045
  39. Giribela C.R, Consolim-Colombo F.M, Nisenbaum M.G et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol 2015; 31 (11): 912-5. doi: 10.3109/09513590.2015.1062860
  40. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 2014; 89: 253-63. doi: 10.1016/j.contraception.2014.01.023
  41. Wang M, Hammarbäck S, Lindhe B.A., Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74: 803-8.
  42. Brown C.S, Ling F.W, Andersen R.N et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779-86.
  43. Cronje W.H, Vashisht A, Studd J.W. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19: 2152-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).